Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Starling Oncology, Inc.TOI · Entity 5327 | Director | December 26, 2023 | December 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Starling Oncology, Inc.
Report date December 26, 2023 · Filed December 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 109,104 |
Reported balance
After 2023-12-26 transaction · row 1
1 source rowRow 1 · 2023-12-26 · Grant · Acquired 50,000 · Balance 109,104 F1: Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest in full on TOI, Inc. 2024 annual shareholder meeting date, subject to continued service with the Company through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CASTLIGHT HEALTH, INC.
Report date January 12, 2022 · Filed February 18, 2022
Section 16 reporting ended · disclosed 2022-02-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 1
1 source rowRow 1 · 2022-02-17 · Disposition to issuer · Disposed 1,625,989 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger (the "Surviving Corporation"), as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash (the "Merger Consideration") at the Effective Time. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 397,500 |
Reported balance
After 2022-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-12 · Grant · Acquired 397,500 · Balance 397,500 F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration. F3: 1/3 of the RSUs vested on February 16, 2022 and the remainder will vest quarterly over two years in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-02-17 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration. F5: Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date. F4: 1/16th of the RSUs vested on February 16, 2018, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-02-17 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration. F5: Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date. F6: 1/16th of the RSUs vested on August 16, 2018, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-02-17 · Disposition to issuer · Disposed 115,313 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration. F5: Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date. F7: 1/16th of the RSUs vested on May 16, 2019, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-02-17 · Disposition to issuer · Disposed 301,725 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration. F5: Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date. F8: 1/16th of the RSUs vested on November 16, 2019, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-02-17 · Disposition to issuer · Disposed 558,000 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration. F5: Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date. F9: 1/16th of the RSUs vested on May 16, 2020, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-02-17 · Disposition to issuer · Disposed 430,625 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration. F5: Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date. F10: 1/16th of the RSUs vested on May 16, 2021, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
| Restricted Stock Units (RSU)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-02-17 · Disposition to issuer · Disposed 397,500 · Balance 0 F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration. F5: Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date. F3: 1/3 of the RSUs vested on February 16, 2022 and the remainder will vest quarterly over two years in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.09 · Expires 2022-11-07 | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-02-17 · Disposition to issuer · Disposed 9,000 · Balance 0 F14: Pursuant to the Merger Agreement, the option was cancelled and converted at or immediately prior to the Effective Time into a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option. F11: The stock option is fully vested and immediately exercisable. F12: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation in effect immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date. F13: Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.12 · Expires 2023-02-11 | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-02-17 · Disposition to issuer · Disposed 7,500 · Balance 0 F14: Pursuant to the Merger Agreement, the option was cancelled and converted at or immediately prior to the Effective Time into a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option. F11: The stock option is fully vested and immediately exercisable. F12: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation in effect immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date. F13: Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.35 · Expires 2023-10-24 | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-02-17 · Disposition to issuer · Disposed 20,000 · Balance 0 F15: The option exercise price is equal to or exceeds the Merger Consideration and therefore the option was automatically cancelled without consideration immediately prior to the Effective Time. F11: The stock option is fully vested and immediately exercisable. F12: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation in effect immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date. F13: Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2026-02-23 | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-02-17 · Disposition to issuer · Disposed 155,000 · Balance 0 F15: The option exercise price is equal to or exceeds the Merger Consideration and therefore the option was automatically cancelled without consideration immediately prior to the Effective Time. F11: The stock option is fully vested and immediately exercisable. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2030-03-02 | Direct | 0 |
Reported balance
After 2022-02-17 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-02-17 · Disposition to issuer · Disposed 331,000 · Balance 0 F17: Pursuant to the Merger Agreement, to the extent vested, the option was cancelled and converted at or immediately prior to the Effective Time into the right to receive a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option. To the extent unvested, the option was cancelled and converted at or immediately prior to the Effective Time into the right to receive a cash replacement amount equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option cash equivalent award valued based on the excess of the Merger Consideration over the option exercise price (the "Option Consideration"). [continued in fn 18]. F18: [cont. from fn. 17] The payment of the Option Consideration will be subject to vesting in accordance with the vesting schedule applicable to the unvested portion of the option immediately prior to the Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date. F16: The option vested as to 1/5th of the total number of shares on March 3, 2021, and thereafter vests as to 1/36th monthly over three years in equal installments, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 4, 2022, by and among the Issuer, Vera Whole Health, Inc. ("Vera Health"), and Carbon Merger Sub, Inc. (the "Merger Sub"), the Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger (the "Surviving Corporation"), as a wholly owned subsidiary of Vera Health, effective as of February 17, 2022 (the "Effective Time"). Pursuant to the Merger Agreement, each share of the Issuer's Class A common stock and Class B common stock was exchanged for $2.05 in cash (the "Merger Consideration") at the Effective Time.
F2: Each RSU represents a contingent right to receive one (1) share of the Class B Common Stock upon settlement for no consideration.
F3: 1/3 of the RSUs vested on February 16, 2022 and the remainder will vest quarterly over two years in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
F4: 1/16th of the RSUs vested on February 16, 2018, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
F5: Pursuant to the Merger Agreement, any RSUs that were unvested at the Effective Time were cancelled and converted at or immediately prior to the Effective Time into the right to receive an amount in cash, without interest, equal to the product of (a) the Merger Consideration multiplied by (b) the total number of unvested shares subject to the RSUs (the "RSU Consideration"). The payment of the RSU Consideration will be subject to vesting in accordance with the vesting schedule applicable to such unvested RSUs immediately prior to Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date.
F6: 1/16th of the RSUs vested on August 16, 2018, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
F7: 1/16th of the RSUs vested on May 16, 2019, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
F8: 1/16th of the RSUs vested on November 16, 2019, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
F9: 1/16th of the RSUs vested on May 16, 2020, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
F10: 1/16th of the RSUs vested on May 16, 2021, and the remainder will vest 1/16th quarterly in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
F11: The stock option is fully vested and immediately exercisable.
F12: Each share of Class A Common Stock is convertible at any time at the option of the holder into one (1) share of Class B Common Stock. In addition, each share of Class A Common Stock will convert automatically into one (1) share of Class B Common Stock upon the transfer, whether or not for value, to any transferee who is not a "Permitted Transferee", as defined in the Issuer's Restated Certificate of Incorporation in effect immediately prior to the Effective Time. The shares of Class A Common Stock have no expiration date.
F13: Each share of Class A Common Stock converted into one (1) share of Class B Common Stock at the Effective Time.
F14: Pursuant to the Merger Agreement, the option was cancelled and converted at or immediately prior to the Effective Time into a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option.
F15: The option exercise price is equal to or exceeds the Merger Consideration and therefore the option was automatically cancelled without consideration immediately prior to the Effective Time.
F16: The option vested as to 1/5th of the total number of shares on March 3, 2021, and thereafter vests as to 1/36th monthly over three years in equal installments, subject to the continuing service of the Reporting Person on each vesting date.
F17: Pursuant to the Merger Agreement, to the extent vested, the option was cancelled and converted at or immediately prior to the Effective Time into the right to receive a cash payment equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option. To the extent unvested, the option was cancelled and converted at or immediately prior to the Effective Time into the right to receive a cash replacement amount equal to the product of (a) the aggregate number of underlying shares multiplied by (b) the excess of the Merger Consideration over the applicable per share exercise price of the option cash equivalent award valued based on the excess of the Merger Consideration over the option exercise price (the "Option Consideration"). [continued in fn 18].
F18: [cont. from fn. 17] The payment of the Option Consideration will be subject to vesting in accordance with the vesting schedule applicable to the unvested portion of the option immediately prior to the Effective Time, subject to the Reporting Person remaining employed by or otherwise in service to the Surviving Corporation on each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · nonDerivative · entry 8 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · kind: Release and settlement of RSUs granted to the Reporting Person on June 11, 2018, the grant of which was previously reported by the Reporting Person on a Form 4. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · nonDerivative · entry 7 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · kind: Release and settlement of RSUs granted to the Reporting Person on March 16, 2018, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · nonDerivative · entry 6 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Release and settlement of RSUs granted to the Reporting Person on March 7, 2017, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 23,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · nonDerivative · entry 5 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Release and settlement of RSUs granted to the Reporting Person on May 16, 2016, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 312 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · nonDerivative · entry 4 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Release and settlement of RSUs granted to the Reporting Person on February 24, 2016, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 3,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · nonDerivative · entry 3 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Release and settlement of RSUs granted to the Reporting Person on November 16, 2015, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | SaleClass B Common Stock | 3,134 | $2.84 | $8,906.83 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · nonDerivative · entry 2 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,786 F2 · shares: Represents the aggregate number of shares sold by the Reporting Person to cover taxes and fees due upon the release and settlement of the RSU's. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.84 to $2.845 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 18:57 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 25,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006812 · doc1.xml · derivative · entry 4 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive1share of the Issuer's Class B common stock upon settlement for no consideration. F1 · kind: Vesting of performance-based RSUs ("PSUs") earned by the Reporting Person on November 16, 2018 as a result of the Reporting Person having met certain performance criteria. F6 · derivative.exercise_date: The RSUs are 100% vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: The RSUs are 100% vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 18:57 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006812 · doc1.xml · derivative · entry 3 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class B Common Stock · 25,000 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents a contingent right to receive1share of the Issuer's Class B common stock upon settlement for no consideration. F5 · shares: Represents PSUs earned by the Reporting Person on November 16, 2018 as a result of the Reporting Person having met certain performance criteria. F6 · derivative.exercise_date: The RSUs are 100% vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F6 · derivative.expiration_date: The RSUs are 100% vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 18:57 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006812 · doc1.xml · nonDerivative · entry 1 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of performance-based RSUs ("PSUs") earned by the Reporting Person on November 16, 2018 as a result of the Reporting Person having met certain performance criteria. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · derivative · entry 9 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Class B Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F1 · kind: Release and settlement of restricted stock units ("RSUs") granted to the Reporting Person on May 15, 2015, the grant of which was previously reported by the Reporting Person on a Form 3. F11 · derivative.exercise_date: 25% of the RSUs vested on February 15, 2016 and the remainder will vest quarterly over three years thereafter in equal installments. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F11 · derivative.expiration_date: 25% of the RSUs vested on February 15, 2016 and the remainder will vest quarterly over three years thereafter in equal installments. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 19:10 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-006702 · doc1.xml · nonDerivative · entry 1 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Release and settlement of restricted stock units ("RSUs") granted to the Reporting Person on May 15, 2015, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | SaleClass B Common Stock | 27,614 | $2.68 | $74,138.07 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · nonDerivative · entry 8 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,920 F8 · shares: Represents the aggregate number of shares sold by the Reporting Person to cover taxes and fees due upon the release and settlement of the RSU's. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F9 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.675 to $2.85 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 20:46 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | SaleClass B Common Stock | 3,284 | $2.87 | $9,414.24 |
DisclosureSEC source: 0001567619-18-001424 · doc1.xml · nonDerivative · entry 2 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,597 F2 · shares: Represents the aggregate number of shares sold by the Reporting Person to cover taxes and fees due upon the release and settlement of the RSU's. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $2.85 to $2.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 17,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · derivative · entry 16 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F7 · kind: Vesting of performance-based RSUs ("PSUs") earned by the Reporting Person on July 10, 2018 as a result of the Reporting Person having met certain performance criteria. F12 · derivative.exercise_date: 100% of the RSUs will vest on August 16, 2018. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F12 · derivative.expiration_date: 100% of the RSUs will vest on August 16, 2018. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · derivative · entry 15 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Class B Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F6 · kind: Release and settlement of RSUs granted to the Reporting Person on June 11, 2018, the grant of which was previously reported by the Reporting Person on a Form 4. F18 · derivative.exercise_date: The RSUs will vest over 4 years in 16 equal quarterly installments beginning on August 16, 2018 until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F18 · derivative.expiration_date: The RSUs will vest over 4 years in 16 equal quarterly installments beginning on August 16, 2018 until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · derivative · entry 14 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Class B Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F5 · kind: Release and settlement of RSUs granted to the Reporting Person on March 16, 2018, the grant of which was previously reported by the Reporting Person on a Form 3. F17 · derivative.exercise_date: The RSUs vested and continue to vest in equal quarterly installments over four years, beginning on February 16, 2018. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting F17 · derivative.expiration_date: The RSUs vested and continue to vest in equal quarterly installments over four years, beginning on February 16, 2018. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 3,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · derivative · entry 13 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Class B Common Stock · 3,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F4 · kind: Release and settlement of RSUs granted to the Reporting Person on March 7, 2017, the grant of which was previously reported by the Reporting Person on a Form 3. F16 · derivative.exercise_date: The RSUs vest over 5 years as follows: 25% of the RSUs vested on March 7, 2018. Thereafter, the shares vest in 12 quarterly installments each consisting of 5% of the shares subject to the RSU, and 1/12 of the remainder vests monthly thereafter until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F16 · derivative.expiration_date: The RSUs vest over 5 years as follows: 25% of the RSUs vested on March 7, 2018. Thereafter, the shares vest in 12 quarterly installments each consisting of 5% of the shares subject to the RSU, and 1/12 of the remainder vests monthly thereafter until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 23,437 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · derivative · entry 12 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,313 Underlying: Class B Common Stock · 23,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F3 · kind: Release and settlement of RSUs granted to the Reporting Person on May 16, 2016, the grant of which was previously reported by the Reporting Person on a Form 3. F15 · derivative.exercise_date: 25% of the RSUs vested on May 16, 2017 and the remainder will vest quarterly over two years thereafter in equal installments. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F15 · derivative.expiration_date: 25% of the RSUs vested on May 16, 2017 and the remainder will vest quarterly over two years thereafter in equal installments. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 313 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · derivative · entry 11 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Class B Common Stock · 313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F2 · kind: Release and settlement of RSUs granted to the Reporting Person on February 24, 2016, the grant of which was previously reported by the Reporting Person on a Form 3. F14 · derivative.exercise_date: The RSUs vest over 5 years as follows: 25% of the RSUs vested on February 24, 2017. Thereafter, the shares vest in 12 quarterly installments each consisting of 5% of the shares subject to the RSU, and 1/12 of the remainder vests monthly thereafter until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F14 · derivative.expiration_date: The RSUs vest over 5 years as follows: 25% of the RSUs vested on February 24, 2017. Thereafter, the shares vest in 12 quarterly installments each consisting of 5% of the shares subject to the RSU, and 1/12 of the remainder vests monthly thereafter until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 3,562 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · derivative · entry 10 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,813 Underlying: Class B Common Stock · 3,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F1 · kind: Release and settlement of restricted stock units ("RSUs") granted to the Reporting Person on November 16, 2015, the grant of which was previously reported by the Reporting Person on a Form 3. F13 · derivative.exercise_date: The RSUs vest over 5 years as follows: 25% of the restricted stock units ("RSUs") vested on November 16, 2016. Thereafter, the shares vest in 12 quarterly installments each consisting of 5% of the shares subject to the RSU, and 1/12 of the remainder vests monthly thereafter until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F13 · derivative.expiration_date: The RSUs vest over 5 years as follows: 25% of the restricted stock units ("RSUs") vested on November 16, 2016. Thereafter, the shares vest in 12 quarterly installments each consisting of 5% of the shares subject to the RSU, and 1/12 of the remainder vests monthly thereafter until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · nonDerivative · entry 7 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Vesting of performance-based RSUs ("PSUs") earned by the Reporting Person on July 10, 2018 as a result of the Reporting Person having met certain performance criteria. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · nonDerivative · entry 6 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: Release and settlement of RSUs granted to the Reporting Person on June 11, 2018, the grant of which was previously reported by the Reporting Person on a Form 4. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · nonDerivative · entry 5 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,534 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Release and settlement of RSUs granted to the Reporting Person on March 16, 2018, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · nonDerivative · entry 4 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: Release and settlement of RSUs granted to the Reporting Person on March 7, 2017, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 23,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · nonDerivative · entry 3 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Release and settlement of RSUs granted to the Reporting Person on May 16, 2016, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 313 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · nonDerivative · entry 2 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Release and settlement of RSUs granted to the Reporting Person on February 24, 2016, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · nonDerivative · entry 1 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Release and settlement of restricted stock units ("RSUs") granted to the Reporting Person on November 16, 2015, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:46 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionRestricted Stock Units · Derivative | 9,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001424 · doc1.xml · derivative · entry 3 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Class B Common Stock · 9,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F1 · kind: Release and settlement of restricted stock units ("RSUs") granted to the Reporting Person on May 15, 2015, the grant of which was previously reported by the Reporting Person on a Form 3. F5 · derivative.exercise_date: 25% of the RSUs vested on February 15, 2016 and the remainder will vest quarterly over three years thereafter in equal installments. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F5 · derivative.expiration_date: 25% of the RSUs vested on February 15, 2016 and the remainder will vest quarterly over three years thereafter in equal installments. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:46 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | Exercise / conversionClass B Common Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001424 · doc1.xml · nonDerivative · entry 1 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Release and settlement of restricted stock units ("RSUs") granted to the Reporting Person on May 15, 2015, the grant of which was previously reported by the Reporting Person on a Form 3. Read SEC document |
| July 10, 2018 Filed Aug 20, 2018 21:44 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | GrantRestricted Stock Units · Derivative | 17,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-001510 · doc1.xml · derivative · entry 9 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Class B Common Stock · 17,500 shares Expires not disclosed F10 · derivative.exercise_price: Each RSU represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F11 · shares: Represents PSUs earned by the Reporting Person on July 10, 2018 as a result of the Reporting Person having met certain performance criteria. F12 · derivative.exercise_date: 100% of the RSUs will vest on August 16, 2018. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F12 · derivative.expiration_date: 100% of the RSUs will vest on August 16, 2018. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 20:47 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | GrantRestricted Stock Units · Derivative | 200,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-028505 · doc1.xml · derivative · entry 1 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Class B Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class B common stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs will vest over 4 years in 16 equal quarterly installments beginning on August 16, 2018 until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. F2 · derivative.expiration_date: The RSUs will vest over 4 years in 16 equal quarterly installments beginning on August 16, 2018 until fully vested. Shares of the Issuer's Class B common stock will be delivered to the Reporting Person following vesting. Read SEC document |
| May 16, 2018 Filed May 17, 2019 17:18 UTC | CASTLIGHT HEALTH, INC. CSLT · Entity 130187 | SaleClass B Common Stock | 8,732 | $3.61 | $31,561.81 |
DisclosureSEC source: 0001567619-19-011571 · doc1.xml · nonDerivative · entry 2 O'Meara Maeve · CIK 0001742487 · EVP,Product&CustomerExperience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,807 F2 · shares: Represents the aggregate number of shares sold by the Reporting Person to cover taxes and fees due upon the release and settlement of the RSUs over several days. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $3.57 to $3.67 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.